Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer in US routine clinical practice

Read full text Summarise with VIRAT
Authors: Hope S. Rugo, Adam Brufsky, Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, A. B. Cohen, Melissa Estévez, Filipa C. Lynce, Paul Henri Cottu, Marc Thill, Giuseppe Curigliano
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Comparative cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) effectiveness data to date are limited to real-world progression-free survival (PFS) and overall survival. Additional effectiveness measures such as time from initial treatment to progression on first subsequent therapy (rwPFS2) and real-world tumor response (rwTR) provide full understanding of CDK4/6i real-world effectiveness. This analysis compared rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving first-line (1L) CDK4/6i plus an aromatase inhibitor (AI) in US routine clinical practice. PATIENTS AND METHODS: P-VERIFY was a retrospective Flatiron Health Research Database analysis of adult patients with HR+/HER2- mBC who started 1L CDK4/6i (palbociclib; ribociclib; abemaciclib) plus AI between February 2015 and November 2023 (N = 9146). rwPFS2 analysis included all 9146 patients while rwTR analysis included 8010 (87.6%) patients who had ≥1 tumor response assessment. Stabilized inverse probability of treatment weighting (sIPTW) was used to balance patient baseline characteristics. A multivariable Cox proportional hazards model was used for sensitivity analysis. RESULTS: After sIPTW, no significant differences were observed across all pairwise treatment comparisons between the CDK4/6i for rwPFS2 and rwTR (all p > 0.05). Findings were generally consistent across subgroups and sensitivity analyses. Findings were also consistent in a separate analysis of patients treated from 2017 onward, corresponding with commercial availability of all three CDK4/6i in the US. CONCLUSIONS: This real-world study demonstrated no statistically significant differences in rwPFS2 and rwTR in patients with HR+/HER2- mBC receiving 1L palbociclib, ribociclib, or abemaciclib, in combination with an AI, in routine clinical practice in the US. CLINICALTRIALS GOV IDENTIFIER: NCT06495164.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication details

Journal / source
The Breast
Volume
87
Pages
104780–104780
Publication date
31 March 2026
Language
EN